Pharmacogenomic approaches to therapies in rheumatic diseases

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

Pharmacogenomics, the study of genetic variations in drug-metabolizing enzymes and their translation to drug effects, is a rapidly evolving field. At the present time, clinicians choose drugs for patients with rheumatologic diseases based on data from population studies and at times, empirically. The application of pharmacogenomics to drugs used in the treatment of rheumatic diseases, particularly the new expensive agents, holds great promise for optimizing their use in clinical practice. In this article, we highlight some of the published literature on the pharmacogenetics of the common disease-modifying antirheumatic drugs (DMARDs) and the emerging data on the new biologic therapies. As evident from the contents of this review, this is an exciting field which is progressing productively and rapidly. Pharmacogenomic approaches are clearly the basis of the "individualized" therapies of the future.

Original languageEnglish
Pages (from-to)161-171
Number of pages11
JournalDrug Development Research
Volume62
Issue number3
DOIs
StatePublished - Jul 1 2004

Keywords

  • Disease-modifying antirheumatic drugs
  • Pharmacogenomics
  • Rheumatic diseases

Fingerprint Dive into the research topics of 'Pharmacogenomic approaches to therapies in rheumatic diseases'. Together they form a unique fingerprint.

  • Cite this